The SARS-CoV-2 Spike (S) glycoprotein mediates the entry of the virus into target cells via its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, thereby initiating the infection. It forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and represents the major target for diagnostic and therapeutic agents. The ectodomain of the S glycoprotein comprises the N-terminal S1 subunit, including the receptor binding domain, and, the C-terminal S2 subunit.
The SARS-CoV-2 Spike-Prot (HEK) protein covers the ectodomain of the viral surface protein including a
Related products for Recombinant SARS-CoV-2 Spike-Prot (HEK)
The SARS-CoV-2 Spike (S) glycoprotein mediates the entry of the virus into target cells via its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, thereby initiating the infection. It forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and represents the major target for diagnostic and therapeutic agents. The ectodomain of the S glycoprotein comprises the N-terminal S1 subunit, including the receptor binding domain, and, the C-terminal S2 subunit.
The SARS-CoV-2 Spike-Prot (HEK) protein covers the ectodomain of the viral surface protein including amino acids V16 to K1211 and contains the stabilizing proline substitutions at position K986P and V987P as well as a mutated Furin cleavage site (RRAR to GSAS substitution at residues 682–685). The protein is extended at its C-terminus with a His-tag and an AviTagTM.
Bead-based immunoassay for detection of patient-derived SARS-CoV-2 antibodies. Schematic overview illustrating how our biotinylated antigens can be applied to detect patient-derived SARS-CoV-2 antibodies
Results of the bead-based immunoassay using biotinylated Recombinant SARS-CoV-2 Spike-Prot (HEK). The amount of captured SARS-CoV-2 antibodies was quantified at different plasma dilutions. Results for plasma from a COVID-19+ patient (circle) or a healthy donor (square) are shown.
Cell-based spike protein binding assay. Schematic overview illustrating how our biotinylated spike proteins can be applied to analyze binding to ACE2-expressing cells.
Results of the cell-based binding assay using biotinylated Recombinant SARS-CoV-2 Spike-Prot (HEK). ACE2-expressing cells (Vero E6 cells) were incubated with biotinylated recombinant SARS-CoV-2 spike monomer (Recombinant SARS-CoV-2 Spike-Prot (HEK)-Biotin). Different protein concentrations were used, and ACE2-bound spike protein was subsequently detected by fluorescent staining with streptavidin-PE. Quantification of stained cells at different protein concentrations illustrates that Miltenyi Biotec's recombinant spike monomer is biologically functional and shows a titratable, high-affinity binding to cell surface ACE2.
SDS-PAGE of biotinylated Recombinant SARS-CoV-2 Spike-Prot (HEK) under reduced (R) and non-reduced (NR) conditions.